Moderna mRNA Flu Vaccine mFlusiva: FDA Support and Investment Outlook

An FDA advisory committee voted unanimously to recommend Moderna’s mRNA-based flu vaccine, “mFlusiva,” for adults aged 50 and older. Late-phase studies show the vaccine is about 27% more effective than conventional flu shots, potentially establishing it as the first mRNA-based flu vaccine if the FDA follows the recommendation.

Did You Know? Late-phase studies indicated that mFlusiva is approximately 27% more effective than conventional flu vaccinations for adults over 50.

Why is mFlusiva significant for older adults?

The vaccine targets adults 50 and older, a group that accounts for the majority of flu-related hospitalizations. According to the advisory committee’s recommendation, the use of mRNA technology could provide a more effective alternative to traditional seasonal shots.

If the FDA and other health authorities approve the vaccine, it would mark the first time an mRNA-based flu shot enters the market. This development would strengthen Moderna’s position in the respiratory vaccine sector for the elderly.

Expert Insight: Samantha Carter notes that transitioning from a COVID-centric model to a broader respiratory portfolio is a strategic necessity. The move toward a seasonal flu product suggests a shift toward recurring revenue streams to offset the decline in pandemic-era demand.

How does this fit into Moderna’s broader strategy?

Moderna is attempting to expand its mRNA platform beyond COVID-19 into specialty medicines and a wider array of respiratory treatments. A June 16 update from the company outlined a business model based on multiple vaccines.

This plan includes up to three potential market launches scheduled for 2027 and 2028, which may include a separate seasonal flu vaccine. mFlusiva serves as a concrete step toward this diversified pipeline.

What are the financial implications and risks?

Financial analysis forecasts Moderna could reach $3.2 billion in revenue and $407.1 million in profit by 2029. However, some analysts have remained cautious, with the most pessimistic predicting annual revenue growth of only 2.5% and at least three years without profit.

In reversal, US FDA will review Moderna's flu vaccine application

Market volatility remains a risk due to the seasonal nature of vaccine demand and ongoing pricing pressures. One analysis suggests a fair value of $46.10 per share, which represents a potential 24% downside from current prices.

Frequently Asked Questions

Who is the mFlusiva vaccine intended for?
The FDA advisory committee recommended the vaccine specifically for adults aged 50 years and older.

How does mFlusiva compare to traditional flu vaccines?
Late-phase studies showed that mFlusiva is roughly 27% more effective than conventional flu vaccinations.

What other launches has Moderna planned?
According to a June 16 update, Moderna is targeting up to three potential market launches in 2027 and 2028, including a separate seasonal flu vaccine.

Do you believe mRNA technology will eventually replace conventional seasonal flu shots?